PART I Overview We are a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. Our lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The product is designed to eliminate residual di...
Q2 FY2026 — expected 2026-09-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-04 | 2025-12-31 | 0001193125-26-089884 | EDGAR | 109K words |
| 2025-03-05 | 2024-12-31 | 0000950170-25-033077 | EDGAR | — |
| 2024-03-06 | 2023-12-31 | 0000950170-24-026875 | EDGAR | — |
| 2023-03-08 | 2022-12-31 | 0000950170-23-006589 | EDGAR | — |
| 2022-03-09 | 2021-12-31 | 0000950170-22-003175 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001193125-25-275933 | EDGAR | 71K words |
| 2025-08-12 | 2025-06-30 | 0000950170-25-106919 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0000950170-25-063968 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-124575 | EDGAR | — |
| 2024-08-12 | 2024-06-30 | 0000950170-24-095066 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0000950170-24-058198 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-061533 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-040961 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0000950170-23-020087 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023507 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0000950170-22-016263 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0000950170-22-009472 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-02 | 0001193125-26-138973 | EDGAR | 1K words |
| 2026-03-04 | 0001193125-26-089871 | EDGAR | — |
| 2026-01-12 | 0001193125-26-009771 | EDGAR | — |
| 2025-11-26 | 0001193125-25-300538 | EDGAR | — |
| 2025-11-12 | 0001193125-25-275889 | EDGAR | — |
| 2025-11-03 | 0001193125-25-261612 | EDGAR | — |
| 2025-09-09 | 0001193125-25-198768 | EDGAR | — |
| 2025-08-20 | 0001193125-25-184083 | EDGAR | — |
| 2025-08-12 | 0000950170-25-106915 | EDGAR | — |
| 2025-07-02 | 0001193125-25-154336 | EDGAR | — |
98 total filings indexed. 71 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001783328 |
| Ticker | TCRX |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.tscan.com |
| Listed | 2021-07-16 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/TCRX (~200 tokens, structured JSON with cryptographic provenance)